c-met inhibitor 2 — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T5349	SCR-1481B1	c-Met inhibitor 2	VEGFR , c-Met/HGFR
	SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor		VEGFR , c-Met/HGFR
T10655	c-Met inhibitor 1		c-Met/HGFR
	c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.		c-Met/HGFR
T13194	CSF1R-IN-2		c-Fms , c-Met/HGFR , Src
	CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).		c-Fms , c-Met/HGFR , Src
T13108	Pamufetinib	H2OL3Q4XRD,4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide,TAS-115	VEGFR , c-Met/HGFR
	Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively).		VEGFR , c-Met/HGFR
T21312	Afatinib	Afatinib free base,BIBW 2992	EGFR , Autophagy
	Afatinib (BIBW 2992) is an irreversible inhibitor of EGFR family (EGFR-wt, EGFR-L858R, EGFR-L858R/T790M and HER2 with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM , respectively).		EGFR , Autophagy
T1773	Afatinib Dimaleate	BIBW2992,Afatinib,BIBW 2992MA2,Afatinib (BIBW2992) Dimaleate	EGFR , HER , Autophagy
	Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic act...		EGFR , HER , Autophagy
T3455	Merestinib	LY2801653	Discoidin Domain Receptor (DDR) , FLT , c-Met/HGFR , ROS , ROS Kinase
	Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. Merestinib electively binds to c-Met, thereby inhibiting c-Met phosph...
T6517	Golvatinib	E-7050	VEGFR , c-Met/HGFR
	Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic ...		VEGFR , c-Met/HGFR
T2054	Altiratinib	DCC-2701	VEGFR , Tie-2 , FLT , Trk receptor , c-Met/HGFR
	Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist...		VEGFR , Tie-2 , FLT , Trk receptor , c-Met/HGFR
T6039	TAK-285	TAK285,TAK 285	EGFR , MEK , HER , Aurora Kinase
	TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.		EGFR , MEK , HER , Aurora Kinase
T2668	JNK-IN-8	JNK Inhibitor XVI	JNK , c-Kit
	JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1/2/4 inhibitor (IC50: 4.7/18.7/1 nM). The selectivity is higher 10-fold than MNK2, Fms and no inhibition of Met, c-Kit, PDGFRβ in A375 cell line.		JNK , c-Kit
T6289	Dovitinib	TKI258,CHIR-258	VEGFR , FGFR , FLT , PDGFR , c-Kit
	Dovitinib (CHIR-258) (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit, IC50: 1/2 nM), also effective to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs (IC50: 8-13 nM), less potent to E...		VEGFR , FGFR , FLT , PDGFR , c-Kit
T6479	Dovitinib lactate hydrate	Dovitinib (TKI258) Lactate,Dovitinib Lactate,TKI258	VEGFR , FGFR , FLT , PDGFR , c-Kit
	Dovitinib lactate hydrate (TKI258) is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) R...		VEGFR , FGFR , FLT , PDGFR , c-Kit
T10654	c-Met-IN-2		c-Met/HGFR
	c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.		c-Met/HGFR
T63656	c-Met-IN-11
	c-Met-IN-11 is a potent inhibitor of c-MET (IC50: 41.4 nM) and VEGFR-2 (IC50: 71.1 nM).
T26379	1D-2	1D2,1D 2
	1D-2 is a highly potent and exquisitely selective inhibitor of the c-Met protein kinase.
T80874	VEGFR-2/c-Met-IN-1		VEGFR
	VEGFR-2/c-Met-IN-1 is a dual inhibitor targeting VEGFR-2 and c-Met with respective IC50 values of 138 nM and 74 nM, demonstrating antitumor activity [1].		VEGFR
T72759	c-Met/HDAC-IN-2
	c-Met/HDAC-IN-2 is a potent dual inhibitor of c-Met and HDAC, exhibiting IC50 values of 5.40 nM for c-Met and 18.49 nM for HDAC1, respectively. It demonstrates antiproliferative effects on various cancer cell lines, indu...
T28899	T-1840383
	T-1840383 is an inhibitor of VEGF-induced VEGFR-2 phosphorylation and HGF-induced c-Met phosphorylation in vascular endothelial cells and cancer epithelial cells.
T71187	Foretinib phosphate
	Foretinib phosphate is an orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vas...